Cumulus NeuLogiq: AI-Enabled Brain Monitoring for CNS Clinical Trials

How Cumulus NeuLogiq’s AI-Enabled Neurotechnology Platform Supports Brain-Function Assessment in Clinical Trials

Cumulus NeuLogiq is an AI-enabled neurotechnology platform that combines EEG recordings with cognitive, mood, speech and sleep assessments to monitor brain function during clinical studies. It addresses a limitation of infrequent, site-based testing: isolated measurements can miss changes between visits. By supporting repeated assessments in clinic and at home, NeuLogiq provides longitudinal data for investigating central nervous system conditions and treatment response.

The platform combines a wireless EEG headset with digital assessments and an analysis pipeline using signal processing and machine learning. EEG captures electrical brain activity alongside behavioural measurements, while proprietary analytics examine patterns across the resulting datasets. Its assessment options include tablet-based cognitive tasks, self-reported mood measures, speech analysis and sleep EEG. The AI analytics are designed for exploratory research, supporting hypotheses and trial insights rather than establishing diagnoses or treatment effectiveness.

Practical benefits include collecting measurements between site visits and examining physiological and behavioural changes within one platform. This can provide a more detailed picture of variation over time while allowing some assessments to take place at home. Integrated operational and analytical support connects trial design, deployment and interpretation; whether these capabilities shorten studies or improve development decisions requires study-specific evidence.

Last checked on 16 October 2026: Cumulus Neuroscience announced a Transpharmation partnership on 14 October to connect preclinical EEG research with early human studies, while NeuLogiq remains available solely for clinical studies.

What is Cumulus NeuLogiq?

Cumulus NeuLogiq is an AI-enabled neurotechnology platform that combines EEG recordings with cognitive, mood, speech and sleep assessments to measure brain function over time in clinical studies. It supports biopharmaceutical sponsors, clinical research teams and study sites through repeated assessments in clinic and at home. Its technical approach combines synchronised physiological and behavioural measurements with signal processing and machine-learning analytics for exploratory research, rather than routine clinical diagnosis or individual consumer use.

Intended Use and Limitations

• The Cumulus Functional Neurophysiology Platform received FDA 510(k) clearance under K221963 in April 2023 for EEG acquisition, display and storage; this does not establish clearance of NeuLogiq’s exploratory AI analytics or diagnostic biomarkers.

• Cumulus describes its EEG headset as UKCA-marked; buyers should verify the current declaration and its scope rather than extend that status to every platform module.

• Company materials reference ISO 13485, HIPAA and GDPR, but current certification scope and supporting privacy documentation were not independently verified in this review.

• NeuLogiq was developed with an advisory group of ten pharmaceutical companies, providing industry input into its clinical-trial measurement requirements rather than endorsement of every analytical output.

• Shionogi selected NeuLogiq to generate neurophysiological data for S-898270 development, providing a named pharmaceutical research application.

• A July 2026 collaboration with Muse by Interaxon adds at-home sleep EEG to NeuLogiq’s multimodal clinical-study assessments.

• An October 2026 partnership with Transpharmation aims to connect preclinical EEG measurements with early human studies; it is a research collaboration, not evidence of validated clinical outcomes.

• A peer-reviewed publication examined at-home cognitive and EEG assessment feasibility in mild Alzheimer’s disease dementia; this supports usability evidence, not validation of every platform biomarker.

• Cumulus raised £3.25 million in July 2025 in a round led by Whiterock’s Growth Capital Fund, supporting commercial expansion without establishing clinical effectiveness.

• NeuLogiq is offered for clinical studies, with machine-learning analytics positioned for exploratory research, rather than routine diagnosis or individual consumer use.